Rajesh Parekh - Galapagos Non-Executive Chairman of the Board

GLPGF Stock  USD 35.52  0.00  0.00%   

Chairman

Dr. Rajesh B. Parekh was NonExecutive Chairman of the Board of Galapagos NV since July 2004. He is also Chairman of the Company Nomination and Remuneration Committee. He is a General Partner at Advent Life Sciences LLP, which he joined in 2006. During an academic career at Oxford University, he cofounded Oxford GlycoSciences PLC, where he served as Chief Scientific Officer and Chief Executive Officer from 1988 until its sale to Celltech Group PLC in 2003. He has founded or served on the boards of several life sciences companies in the United States and Europe including Celldex Therapeutics, Inc. Avila Therapeutics, Inc. EUSA Pharma Limited Thiakis Limited and Amsterdam Molecular Therapeutics Holding N.V. . Dr. Parekh currently serves as a member of the board of directors of Advent Venture Partners Advent Life Sciences LLP Aleta Inc. Arrakis, Inc. Aura Inc. Artax Inc. Capella BioSciences Ltd. Cellnovo Limited EnCipher Limited Itara Limited Levicept Limited Macrolide Pharmaceuticals, Inc. PE Limited and Project Paradise Limited. He is also a member of the supervisory board of the Novartis Venture Fund. During the past five years, he served as a member of the board of directors of Biocartis NV, 4Antibody AG, NeRRe Therapeutics Limited, F2G Limited, LuxFold S.A., CoCo Therapeutics Limited. He received his MA in Biochemistry and DPhil in Molecular Medicine from the University of Oxford, where he was a Senior Research Fellow and Professor. since 2004.
Age 57
Tenure 20 years
Phone32 1 534 29 00
Webhttps://www.glpg.com

Galapagos Management Efficiency

The company has return on total asset (ROA) of (0.0119) % which means that it has lost $0.0119 on every $100 spent on assets. This is way below average. Galapagos' management efficiency ratios could be used to measure how well Galapagos manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 24.05 M in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Galapagos NV has a current ratio of 8.07, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Galapagos until it has trouble settling it off, either with new capital or with free cash flow. So, Galapagos' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Galapagos NV sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Galapagos to invest in growth at high rates of return. When we think about Galapagos' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 12 records

CHAIRMAN Age

Jeffrey LeidenVertex Pharmaceuticals
62
Roy VagelosRegeneron Pharmaceuticals
88
Joshua BogerVertex Pharmaceuticals
63
Jeppe ChristiansenNovo Nordisk AS
61
Uli HacksellModerna
67
Helge LundNovo Nordisk AS
58
Rodney McMullenKroger Company
55
Goran AndoNovo Nordisk AS
67
Vuong TrieuModerna
50
Michael FrenchModerna
54
William McMullenKroger Company
63
Jeffrey MDVertex Pharmaceuticals
68
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium. Galapagos Genomics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1344 people. Galapagos NV [GLPGF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Galapagos NV Leadership Team

Elected by the shareholders, the Galapagos' board of directors comprises two types of representatives: Galapagos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galapagos. The board's role is to monitor Galapagos' management team and ensure that shareholders' interests are well served. Galapagos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galapagos' outside directors are responsible for providing unbiased perspectives on the board's policies.
Rajesh Parekh, Non-Executive Chairman of the Board
Andre Hoekema, Sr. VP of Corporate Devel.
Katrine Bosley, Independent Non-Executive Director
John Montana, Managing Argenta
Walid AbiSaab, Member of the Executive Committee, Chief Medical Officer
Marieke Vermeersch, Head Communication
Howard Rowe, Non-Executive Independent Director
Bob Rajan, Non-Executive Independent Director
Harrold Barlingen, Non-Executive Director
Raj Parekh, Non-Executive Chairman of the Board
Elizabeth Goodwin, VP Corporate Communications & Investor Relations
Mary Kerr, Non-Executive Independent Director
Michele MBA, Chief Board
Piet Wigerinck, Chief Scientific Officer
Chantal Tasset, Head Devel
Sofie Gijsel, Head Relations
MBA MBA, COO Pres
Bart Filius, CFO
Christine Mummery, Non-Executive Independent Director
Werner Cautreels, Non-Executive Independent Director
Onno Stolpe, Co-Founder, CEO, Managing Director and Executive Director

Galapagos Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Galapagos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galapagos NV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the Galapagos NV information on this page should be used as a complementary analysis to other Galapagos' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Galapagos Pink Sheet analysis

When running Galapagos' price analysis, check to measure Galapagos' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galapagos is operating at the current time. Most of Galapagos' value examination focuses on studying past and present price action to predict the probability of Galapagos' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galapagos' price. Additionally, you may evaluate how the addition of Galapagos to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Bonds Directory
Find actively traded corporate debentures issued by US companies
Please note, there is a significant difference between Galapagos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galapagos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galapagos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.